

# Brenton G Mar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4242923/publications.pdf>

Version: 2024-02-01

32  
papers

6,745  
citations

430442

18  
h-index

500791

28  
g-index

32  
all docs

32  
docs citations

32  
times ranked

11198  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Whole exome sequencing of a breast tumor in a patient with Diamond Blackfan anemia. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 89, 102566.   | 0.6  | 0         |
| 2  | Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF). <i>Leukemia Research</i> , 2021, 108, 106606.  | 0.4  | 6         |
| 3  | Effective Control of Advance Systemic Mastocytosis with Avapritinib: Mutational Analysis from the Explorer Clinical Study. <i>Blood</i> , 2021, 138, 318-318.   | 0.6  | 16        |
| 4  | PIONEER: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis (SM) With Symptoms Inadequately Controlled by Standard Therapy. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, AB336. | 1.5  | 15        |
| 5  | Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy. <i>Blood</i> , 2019, 134, 2950-2950.                                     | 0.6  | 2         |
| 6  | Diagnosis and Treatment of Acute Myeloid Leukemia in Children. , 2018, , 359-374.   |      | 0         |
| 7  | PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. <i>Blood</i> , 2018, 132, 1095-1105.   | 0.6  | 160       |
| 8  | Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1598-1605.   | 0.8  | 339       |
| 9  | Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with <i>TP53</i> mutations. <i>EMBO Molecular Medicine</i> , 2017, 9, 498-507.   | 3.3  | 86        |
| 10 | Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2017, 376, 536-547.  | 13.9 | 586       |
| 11 | The relative utilities of genome-wide, gene panel, and individual gene sequencing in clinical practice. <i>Blood</i> , 2017, 130, 433-439.  | 0.6  | 50        |
| 12 | The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia. <i>Blood</i> , 2017, 129, 497-508.   | 0.6  | 65        |
| 13 | SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia. <i>Blood</i> , 2017, 130, 2631-2641.  | 0.6  | 102       |
| 14 | Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , 2016, 126, 3827-3836.  | 3.9  | 40        |
| 15 | Genetic Alterations Predict Outcomes in Patients with Myelodysplastic Syndrome Receiving Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 69-69.   | 0.6  | 2         |
| 16 | Clonal Hematopoiesis Associated with Adverse Outcomes Following Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 986-986.   | 0.6  | 3         |
| 17 | Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. <i>Blood</i> , 2015, 125, 1367-1376.  | 0.6  | 747       |
| 18 | SETD2 Heterozygous Loss in Leukemia Leads to Chemotherapy Resistance through Attenuation of the DNA Damage Response. <i>Blood</i> , 2015, 126, 2626-2626.   | 0.6  | 0         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes. <i>New England Journal of Medicine</i> , 2014, 371, 2488-2498.  | 13.9 | 3,474     |
| 20 | Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 2691-2698.     | 0.8  | 359       |
| 21 | Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. <i>Nature Communications</i> , 2014, 5, 3469.                        | 5.8  | 171       |
| 22 | Ontogeny-Specific Patterns of Genetic Alterations in Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 18-18.  | 0.6  | 0         |
| 23 | Clonal Hematopoiesis with Somatic Mutations Is a Common, Age-Related Condition Associated with Adverse Outcomes. <i>Blood</i> , 2014, 124, 840-840.  | 0.6  | 1         |
| 24 | Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia. <i>Leukemia</i> , 2012, 26, 1881-1883.  | 3.3  | 70        |
| 25 | The controversial role of the Hedgehog pathway in normal and malignant hematopoiesis. <i>Leukemia</i> , 2011, 25, 1665-1673.   | 3.3  | 58        |
| 26 | Self-renewal related signaling in myeloid leukemia stem cells. <i>International Journal of Hematology</i> , 2011, 94, 109-117.   | 0.7  | 41        |
| 27 | CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. <i>Nature</i> , 2009, 459, 1000-1004.   | 13.7 | 227       |
| 28 | Knockdown of CCR7 or Its Ligands Causes a Loss of Central Nervous System Involvement in Notch1 Induced T-ALL. <i>Blood</i> , 2008, 112, 199-199.   | 0.6  | 4         |
| 29 | Genetic Engineering and Significant Ex-Vivo Expansion of Cord Blood Natural Killer Cells: Implications for Post-Transplant Adoptive Cellular Immunotherapy. <i>Blood</i> , 2008, 112, 209-209. | 0.6  | 1         |
| 30 | Membrane-Associated and Secreted Genes in Breast Cancer. <i>Cancer Research</i> , 2004, 64, 8682-8687.   | 0.4  | 17        |
| 31 | Novel transcription factors in human CD34 antigen <sup>+</sup> positive hematopoietic cells. <i>Blood</i> , 2002, 100, 107-119.  | 0.6  | 32        |
| 32 | A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31. <i>Oncogene</i> , 2001, 20, 6946-6954.                       | 2.6  | 71        |